natgillin/translations-raw huggingface dataset:
Subsequently, the Commission went back to the Authority to seek further advice to enable the risk managers to set appropriate conditions of use for the relevant health claims.
Vendar je Agencija ugotovila, da predložene informacije niso bile zadostne za določitev pogojev uporabe trditev.
The Authority concluded in its opinion received by the Commission and the Member States on 17 May 2010 (Question No EFSA-Q-2009-00940) [3] that at least 1200 mg of calcium from all sources or at least 1200 mg of calcium and 800 I.U.
Zato se je Komisija ponovno obrnila na Agencijo za dodatni nasvet, ki bi odgovornim za obvladovanje tveganja omogočil, da določijo ustrezne pogoje uporabe zadevnih zdravstvenih trditev.
(20 μg) of vitamin D from all sources should be consumed daily in order to obtain the claimed effect.
Agencija je v mnenju, ki so ga Komisija in države članice prejele 17. maja 2010 (vprašanje št.
When the health claim is made only on calcium, in order to ensure that a food provides a significant quantity of calcium, it is appropriate to set conditions of use which allow the claim to be made only on foods which provide at least 400 mg of calcium per quantified portion.
EFSA-Q-2009-00940) [3], ugotovila, da je za doseganje navedenega učinka potrebno zaužiti vsaj 1200 mg kalcija iz vseh virov ali vsaj 1200 mg kalcija in 800 i.e.
Taking into account the high level of vitamin D intake required to achieve the claimed effect (20 μg), when the health claim is made on the combination of calcium and vitamin D, it is appropriate to limit the use of the claim to food supplements.
(20 μg) vitamina D iz vseh virov.
In order to ensure that a food supplement would provide a significant quantity of calcium and vitamin D in the context of this claim, it is appropriate to set conditions of use which allow the claim to be made only on food supplements which provide at least 400 mg of calcium and 15 μg of vitamin D per daily portion.
Kadar se zdravstvena trditev uporablja le za kalcij, je za zagotovitev, da živilo vsebuje zadostno količino kalcija, primerno določiti pogoje uporabe, ki določajo uporabo trditve le na živilih, ki zagotavljajo vsaj 400 mg kalcija v količinsko določenem obroku.
Following an application from DSM Nutritional Products Europe AG, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of vitamin D and risk of falling for men and women 60 years of age and older (Question No EFSA-Q-2010-01233) [4].
Kadar se zdravstvena trditev uporablja za kombinacijo kalcija in vitamina D, je treba za doseganje navedenega učinka zaužiti precejšnjo količino vitamina D (20 μg), zato je primerno uporabo trditve omejiti na prehranska dopolnila.
The claim proposed by the applicant was worded as follows: ‘Vitamin D reduces the risk of falling.
Za zagotovitev, da prehransko dopolnilo, na katerem se uporablja navedena trditev, zagotavlja znatno količino kalcija in vitamina D, je primerno določiti pogoje uporabe, ki določajo uporabo trditve le na prehranskih dopolnilih, ki zagotavljajo vsaj 400 mg kalcija in 15 μg vitamina D v dnevnem obroku.
Falling is a risk factor for fractures’.
Družba DSM Nutritional Products Europe AG je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki vitamina D na tveganje za padce pri moških in ženskah po 60. letu starosti (vprašanje št.
A reduction in the risk of falling among men and women 60 years of age and older is beneficial to human health by reducing the risk of bone fractures.
Vložnik je predlagal naslednjo trditev: „Vitamin D zmanjša tveganje za padce.
Accordingly, a health claim reflecting this conclusion should be considered as complying with the requirements of Regulation (EC) No 1924/2006, and should be included in the Uni on list of permitted claims.
Padci so dejavnik tveganja za zlome.“
In its opinion, the Authority also concluded that 800 I.U.
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 30. septembra 2011, ugotovila, da je vzročno-posledična povezava med uživanjem vitamina D in zmanjšanjem tveganja za padce, ki so posledica posturalne nestabilnosti in mišične oslabelosti, utemeljena.
(20 μg) of vitamin D, from all sources, should be consumed daily in order to obtain the claimed effect.
Zmanjšanje tveganja za padce pri moških in ženskah po 60. letu starosti je koristno za zdravje ljudi, saj se zmanjša tveganje za kostne zlome.
Taking into account the high level of vitamin D intake required to achieve the claimed effect (20 μg), it is appropriate to limit the use of the claim to food supplements.
Agencija je v mnenju tudi ugotovila, da je treba za doseganje navedenega učinka dnevno zaužiti 800 i.e.
In order to ensure that a food supplement would provide a significant quantity of vitamin D in the context of this claim, it is appropriate to set conditions of use which allow the claim to be made only on food supplements which provide at least 15 μg of vitamin D per daily portion.
(20 μg) vitamina D iz vseh virov.
Article 16(4) of Regulation (EC) No 1924/2006 provides that an opinion in favour of authorising a health claim should include certain particulars.
Ker je treba za doseganje navedenega učinka zaužiti precejšnjo količino vitamina D (20 μg), je primerno uporabo trditve omejiti na prehranska dopolnila.
Accordingly, those particulars should be set out in Annex I to this Regulation as regards the authorised claims and include, as the case may be, the revised wording of the claim, specific conditions of use of the claim, and, where applicable, conditions or restrictions of use of the food and/or an additional statement or warning, in accordance with the rules laid down in Regulation (EC) No 1924/2006 and in line with the opinions of the Authority.
Za zagotovitev, da prehransko dopolnilo, na katerem se uporablja navedena trditev, zagotavlja znatno količino vitamina D, je primerno določiti pogoje uporabe, ki določajo uporabo trditve le na prehranskih dopolnilih, ki zagotavljajo vsaj 15 μg vitamina D v dnevnem obroku.
One of the objectives of Regulation (EC) No 1924/2006 is to ensure that health claims are truthful, clear and reliable and useful to the consumer, and that wording and presentation are taken into account in that respect.
Člen 16(4) Uredbe (ES) št. 1924/2006 določa, da bi moralo mnenje, ki podpira odobritev zdravstvene trditve, vključevati nekatere podatke.
Therefore where the wording of claims has the same meaning for consumers as that of an authorised health claim, because they demonstrate the same relationship that exists between a food category, a food or one of its constituents and health, they should be subject to the same conditions of use indicated in Annex I to this Regulation.
Navedene podatke v zvezi z odobrenimi trditvami bi zato bilo treba določiti v Prilogi I k tej uredbi ter vanje vključiti, odvisno od primera, spremenjeno besedilo trditve, posebne pogoje uporabe trditve in, kadar je to ustrezno, pogoje ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo v skladu s pravili iz Uredbe (ES) št. 1924/2006 in mnenji Agencije.
Following an application from GP International Holding B.V., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glucosamine hydrochloride and reduced rate of cartilage degeneration (Question No EFSA-Q-2009-00412) [5].
Eden od ciljev Uredbe (ES) št. 1924/2006 je zagotoviti, da so zdravstvene trditve resnične, jasne, zanesljive in uporabne za potrošnika ter da se pri tem upoštevata besedilo in predstavitev trditve.
The claim proposed by the applicant was worded as follows: ‘Slowing down/reduce the destruction process of cartilage of the musculoskeletal system and consequently reduce the risk of osteoarthritis’.
Kadar ima besedilo trditev za potrošnike enak pomen kot odobrena zdravstvena trditev, ker je med njima ista povezava kot med kategorijo živila, živilom ali njegovo sestavino in zdravjem, bi bilo treba te trditve uporabljati pod istimi pogoji, kot so navedeni v Prilogi I k tej uredbi.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 29 October 2009 that a cause and effect relationship had not been established between the consumption of glucosamine hydrochloride and the claimed effect.
Družba GP International Holding B.V. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki glukozamin hidroklorida na zmanjšanje hitrosti degeneracije hrustanca (vprašanje št.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
EFSA-Q-2009-00412) [5].
Following an application from the European Natural Soyfood Manufacturers Association (ENSA), the European Vegetable Protein Federation (EUVEPRO) and the Soya Protein Association (SPA), submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of isolated soy protein on reduction of blood LDL-cholesterol concentrations (Question No EFSA-Q-2011-00784) [6].
Vložnik je predlagal naslednjo trditev: „Upočasni/zmanjša postopek uničevanja hrustanca v mišično-skeletnem sistemu in posledično zmanjša tveganje za osteoartritis.“
The claim proposed by the applicant was worded as follows: ‘Protein-rich soybean component has been shown to lower/reduce blood cholesterol; blood cholesterol lowering may reduce the risk of (coronary) heart disease’.
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 29. oktobra 2009, ugotovila, da vzročno-posledična povezava med uživanjem glukozamin hidroklorida in navedeno trditvijo ni bila utemeljena.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 2 February 2012 that a cause and effect relationship had not been established between the consumption of isolated soy protein, as defined by the applicant, and the claimed effect.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
Following an application from Health Concern B.V., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a combination of plant sterols and Cholesternorm®mix and reduction of blood LDL-cholesterol concentrations (Question No EFSA-Q-2009-00237, EFSA-Q-2011-01114) [7].
Evropsko združenje proizvajalcev naravnih živil iz soje (European Natural Soyfood Manufacturers Association, ENSA), Evropska zveza za rastlinske beljakovine (European Vegetable Protein Federation, EUVEPRO) in Združenje za sojine beljakovine (Soya Protein Association, SPA) so v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložili vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki izolirane sojine beljakovine na znižanje koncentracije LDL-holesterola v krvi (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Actively lowers cholesterol’.
EFSA-Q-2011-00784) [6].
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 17 July 2012 that a cause and effect relationship had not been established between the consumption of a combination of plant sterols and Cholesternorm®mix and the claimed effect at the proposed conditions of use.
Vložnik je predlagal naslednjo trditev: „Beljakovinsko bogata sestavina soje dokazano znižuje holesterol v krvi.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Znižanje holesterola v krvi lahko zmanjša tveganje za (koronarno) bolezen srca.“
Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of eicosapentaenoic acid (EPA) on a reduction of the Arachidonic Acid (AA)/EPA ratio in blood in children with attention deficit hyperactivity disorder (ADHD) (Question No EFSA-Q-2012-00573) [8].
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 2. februarja 2012, ugotovila, da vzročno-posledična povezava med uživanjem izolirane sojine beljakovine, kot jo je opredelil vložnik, in navedeno trditvijo ni bila utemeljena.
The claim proposed by the applicant was worded as follows: ‘EPA has been shown to reduce the AA/EPA ratio in blood.
Družba Health Concern B.V. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije rastlinskih sterolov in mešanice Cholesternorm® na znižanje koncentracije LDL-holesterola v krvi (vprašanji št.
A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms.
EFSA-Q-2009-00237, EFSA-Q-2011-01114) [7].
These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour’.
Vložnik je predlagal naslednjo trditev: „Aktivno znižuje holesterol.“
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 8 April 2013 that the target population for the claim is a diseased population (i.e. children with ADHD) and that the claimed effect relates to the treatment of a disease.
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 17. julija 2012, ugotovila, da vzročno-posledična povezava med uživanjem kombinacije rastlinskih sterolov in mešanice Cholesternorm® pod predlaganimi pogoji uporabe ter navedeno trditvijo ni bila utemeljena.
Regulation (EC) No 1924/2006 complements the general principles of Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws of the Member States relating to the labelling, presentation and advertising of foodstuffs [9].
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
Article 2(1)(b) of Directive 2000/13/EC provides that the labelling shall not attribute to any foodstuff the property of preventing, treating or curing a human disease, or refer to such properties.
Družba Minami Nutrition Health BVBA je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki eikozapentaenojske kisline (EPA) na znižanje razmerja arahidonska kislina (AA)/EPA v krvi otrok s primanjkljajem pozornosti in motnjo hiperaktivnosti (ADHD) (vprašanje št.
Accordingly, as the attribution of medicinal properties to foods is prohibited, the claim related to the effects of eicosapentaenoic acid (EPA) on a reduction of the AA/EPA ratio in blood in children with ADHD should not be authorised.
EFSA-Q-2012-00573) [8].
Following an application from McNeil Nutritionals and Raisio Nutrition Ltd, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of 2 g/day of plant stanols (as plant stanol esters) as part of a diet low in saturated fat and a two-fold greater reduction in blood LDL-cholesterol concentrations compared to the consumption of a diet low in saturated fat alone (Question No EFSA-Q-2012-00915) [10].
Vložnik je predlagal naslednjo trditev: „EPA dokazano znižuje razmerje AA/EPA v krvi.
The claim proposed by the applicant was worded as follows: ‘Consuming 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a 2-fold greater reduction in LDL-cholesterol than consuming a low saturated fat diet alone.
Visoko razmerje AA/EPA je dejavnik tveganja za nastanek motenj pozornosti pri otrocih s simptomi, podobnimi ADHD.
High cholesterol is a risk factor in the development of coronary heart disease’.
Za te otroke je prav tako značilna manjša hiperaktivnost in/ali sočasno nasprotujoče obnašanje.“
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 8 April 2013 that the evidence provided by the applicant does not establish that the consumption of 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a two-fold greater reduction in LDL-cholesterol concentrations compared with consuming a diet low in saturated fat alone.
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 8. aprila 2013, ugotovila, da so ciljna populacija za trditev bolniki (tj. otroci z ADHD) in da se navedena trditev nanaša na zdravljenje bolezni.
The comments from the applicants and the members of the public received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
Uredba (ES) št. 1924/2006 dopolnjuje splošne določbe Direktive 2000/13/ES Evropskega parlamenta in Sveta z dne 20. marca 2000 o približevanju zakonodaje držav članic o označevanju, predstavljanju in oglaševanju živil [9].
The addition of substances to or the use of substances in foodstuffs is governed by specific Union and national legislation, as is the classification of products as foodstuffs or medicinal products.
Člen 2(1)(b) Direktive 2000/13/ES določa, da označevanje živilom ne sme pripisovati lastnosti, ko t so preprečevanje, zdravljenje ali ozdravljenje bolezni pri ljudeh ali opozarjati na take lastnosti.
Any decision on a health claim in accordance with Regulation (EC) No 1924/2006 such as inclusion in the list of permitted claims referred to in Article 14(1) thereof does not constitute an authorisation to the marketing of the substance on which the claim is made, a decision on whether the substance can be used in foodstuffs, or a classification of a certain product as a foodstuff.
Ker je pripisovanje zdravilnih lastnosti živilom prepovedano, se trditev v zvezi z učinki eikozapentaenojske kisline (EPA) na znižanje razmerja AA/EPA v krvi otrok z ADHD ne bi smela odobriti.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,
Družba McNeil Nutritionals and Raisio Nutrition Ltd. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi, da uživanje 2 g/dan rastlinskih stanolov (v obliki estrov rastlinskih stanolov) v okviru prehrane z nizko vsebnostjo nasičenih maščob zniža koncentracijo LDL-holesterola v krvi dvakrat več kot le prehrana z nizko vsebnostjo nasičenih maščob (vprašanje št.
HAS ADOPTED THIS REGULATION:
EFSA-Q-2012-00915) [10].
Article 1
Vložnik je predlagal naslednjo trditev: „Uživanje 2 g/dan rastlinskih stanolov (v obliki estrov rastlinskih stanolov) v okviru prehrane z nizko vsebnostjo nasičenih maščob, zniža LDL-holesterol dvakrat več kot le prehrana z nizko vsebnostjo nasičenih maščob.
The health claims listed in Annex I to this Regulation may be made on foods placed on the Union market in compliance with the conditions laid down in that Annex.
Povišan holesterol je dejavnik tveganja za razvoj koronarne bolezni srca.“
The health claims referred to in paragraph 1 shall be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 8. aprila 2013, ugotovila, da iz dokazov, ki jih je predložil vložnik, ni mogoče sklepati, da uživanje 2 g/dan rastlinskih stanolov (v obliki estrov rastlinskih stanolov) v okviru prehrane z nizko vsebnostjo nasičenih maščob zniža koncentracijo LDL-holesterola v krvi dvakrat več kot le prehrana z nizko vsebnostjo nasičenih maščob.
Article 2
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vložniki in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
The health claims listed in Annex II to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Dodajanje snovi živilom oziroma njihovo uporabo v živilih ter razvrstitev proizvodov med živila ali zdravila urejata posebna zakonodaja Unije in nacionalna zakonodaja.
Article 3
Vsaka odločitev o zdravstveni trditvi v skladu z Uredbo (ES) št. 1924/2006, kot je vključitev na seznam dovoljenih trditev iz člena 14(1) navedene uredbe, ne pomeni dovoljenja za trženje snovi, na katero se trditev nanaša, odločitve o tem, ali se snov lahko uporablja v živilih, ali uvrstitve določenega proizvoda med živila.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Ukrepi iz te uredbe so v skladu z mnenjem Stalnega odbora za prehranjevalno verigo in zdravje živali –
This Regulation shall be binding in its entirety and directly applicable in all Member States.
SPREJELA NASLEDNJO UREDBO:
Done at Brussels, 17 November 2014.
Člen 1
For the Commission
Zdravstvene trditve iz Priloge I k tej uredbi se lahko navedejo na živilih, ki se dajejo na trg Evropske unije, v skladu s pogoji iz navedene priloge.
The President
Zdravstvene trditve iz odstavka 1 se uvrstijo na seznam dovoljenih trditev Unije v skladu s členom 14(1) Uredbe (ES) št. 1924/2006.
OJ L 404, 30.12.2006, p. 9.
Člen 2
EFSA Journal (2009) 1180, 1-13.
Zdravstvene trditve iz Priloge II k tej uredbi se ne uvrstijo na seznam dovoljenih trditev Unije v skladu s členom 14(1) Uredbe (ES) št. 1924/2006.
EFSA Journal (2010);8(5):1609.
Člen 3
EFSA Journal (2011);9(9):2382.
Ta uredba začne veljati dvajseti dan po objavi v Uradnem listu Evropske unije.
EFSA Journal 2009;7(10):1358.
Ta uredba je v celoti zavezujoča in se neposredno uporablja v vseh državah članicah.
EFSA Journal 2012;10(2):2555.
V Bruslju, 17. novembra 2014
EFSA Journal 2012;10(7):2810.
Za Komisijo
EFSA Journal 2013;11(4):3161.
Predsednik
OJ L 109, 6.5.2000, p. 29.
UL L 404, 30.12.2006, str. 9.
EFSA Journal 2013;11(4):3160.
EFSA Journal 2009; 1180, 1–13.
ANNEX I
EFSA Journal 2010; 8(5):1609.
Permitted health claims
EFSA Journal 2011; 9(9):2382.
Application — Relevant provisions of Regulation (EC) No 1924/2006
EFSA Journal 2009; 7(10):1358.
Applicant — Address
EFSA Journal 2012; 10(2):2555.
Nutrient, substance, food or food category
EFSA Journal 2012; 10(7):2810.
Conditions of use of the claim
UL L 109, 6.5.2000, str. 29.
Conditions and/or restrictions of use of the food and/or additional statement or warning
EFSA Journal 2013; 11(4):3160.
EFSA opinion reference
PRILOGA I
Article 14(1)(a) health claim referring to a reduction of a disease risk
Dovoljene zdravstvene trditve
Abtei Pharma Vertriebs GmbH, Abtei 1, 37696, Marienműnster, Germany .
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Calcium
Vložnik – naslov
Calcium helps to reduce the loss of bone mineral in post-menopausal women.
Hranilo, snov, živilo ali kategorija živil
Low bone mineral density is a risk factor for osteoporotic bone fractures
Trditev
The claim may be used only for food which provides at least 400 mg of calcium per quantified portion.
Pogoji uporabe trditve
Information shall be given to the consumer that the claim is specifically intended for women 50 years and older and the beneficial effect is obtained with a daily intake of at least 1200 mg of calcium from all sources.
Pogoji in/ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo
For foods with added calcium the claim may be used only for those targeting women 50 years and older
Referenčno mnenje Agencije za varnost hrane
The claim may be used only for food supplements which provide at least 400 mg of calcium and 15 μg of vitamin D per daily portion.
Kalcij prispeva k zmanjšanju izgube mineralne kostne gostote pri ženskah po menopavzi.